EUNETWORKS
31.12.2020 11:08:17 CET | Business Wire | Press release
euNetworks Fiber UK Limited (“euNetworks”), a Western European bandwidth infrastructure company, today announced that it has acquired 100% of the shares of The Loop Manchester Limited (“The Loop”), from Gamma Telecom Holdings Limited (“Gamma”). The Loop is a duct and sub-duct based fibre network in Greater Manchester in the United Kingdom.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201231005050/en/
The Loop launched in 2012 and has a unique duct network stretching more than 87km across the key commercial areas of Manchester, Salford and Trafford. With over 180km of high capacity fibre cables, it connects into 20 data centres, two Exchanges and provides high capacity internet into more than 70 key multi-tenant commercial buildings. Approximately 48km of the duct network is entirely unique routing from alternative operators in the city. That routing combined with 700 chambers and expansion capability, offers a strong compliment to euNetworks current fibre network in Manchester. As well as serving the growing Manchester media sector, The Loop’s customers include major data centre operators, enterprises and public sector organisations.
euNetworks is focused on delivering high bandwidth fibre connectivity between and within cities in Europe. The company owns and operates deep fibre networks in 17 cities, including Manchester, and also operates a highly differentiated long haul network that spans 15 countries. euNetworks continues to invest in its network, building unique routes, adding multiple diverse paths and extending reach into key hyperscale data centre sites, data centre clusters and network aggregation points. These investments continue to fuel the company’s growth and are driven by the capacity requirements of euNetworks’ customers. At the heart of this is the company’s direct, diverse connectivity to over 440 data centres across Western Europe.
“Manchester is an important and growing digital hub and we have been keen to develop our presence in the city for some time. It also enhances our Super Highway that runs from Dublin through to Manchester, London and Lowestoft,” said Brady Rafuse, Chief Executive Officer of euNetworks. “The acquisition of The Loop network strengthens our customer proposition in the bandwidth infrastructure market. As well as adding unique routes to our Manchester metro, the Loop provides us with a more local presence, the flexibility to connect more data centres and buildings and the opportunity for further expansion. Prior to this acquisition, our Manchester metro consisted of 42km of duct network, 276 chambers and direct connection into 17 data centres. The combined footprint will deliver immediate value to both existing customers and our new customers that we welcome from The Loop.”
Andrew Taylor, Gamma’s Chief Executive Officer, commented: “We have developed The Loop into a successful and growing business which is now ready for its next phase and we’re really pleased that euNetworks has chosen to be its ensuing owner. euNetworks’ extensive fibre footprint across Europe and the UK coupled with their customer centred approach to network development and investment is both impressive and innovative.”
“This is a great match for The Loop and we are delighted to have been acquired by euNetworks and to be joining the team,” said Ashley Griffiths, Managing Director of The Loop. “We’ve worked closely with euNetworks for a number of years in Manchester and I know our customers will immediately benefit from this acquisition. We remain focused on delivering a great service experience as well as more fibre-based service options to our customers.”
“We anticipate a rapid integration of The Loop into euNetworks,” added Rafuse. “We are delighted to welcome Ashley and the team into the euNetworks group along with their customers and suppliers. Their local knowledge, expertise, impressive development and strong relationships in the market are invaluable as we look to grow euNetworks’ presence in the region. In addition, our focus on the media sector is immediately strengthened with their knowledge and strong reputation among the media and broadcast community in Manchester and the UK. There’s a great opportunity from the teams and the networks coming together to develop and future-proof some of the larger content requirements of these companies.”
About euNetworks
euNetworks is a bandwidth infrastructure company, owning and operating 17 fibre based metropolitan networks connected with a high capacity intercity backbone covering 51 cities in 15 countries across Europe. The company leads the market in data centre connectivity, directly connecting over 440 today. euNetworks is also a leading cloud connectivity provider and offers a targeted portfolio of metropolitan and long haul services including Dark Fibre, Wavelengths, and Ethernet. Wholesale, finance, content, media, mobile, data centre and enterprise customers benefit from euNetworks’ unique inventory of fibre and duct based assets that are tailored to fulfil their high bandwidth needs. For further information visit eunetworks.com .
About Gamma
Gamma is a leading supplier of Unified Communications as a Service (UCaaS) in the UK, German, Spanish and Dutch business markets. It is AIM listed and employs 1450 people. With a range of UCaaS, Mobile and Connectivity services, Gamma provides robust and secure solutions that enable organisations to communicate, collaborate and offer a better customer experience. Gamma focuses its family of businesses on digital automation, delivering UCaaS services to SME customers largely via a network of channel partners. For further information visit www.gammacommunicationsplc.com
About The Loop Manchester Ltd
The Loop Manchester is more than 180km of fibre network, supplying direct connectivity to data centres and ultrafast internet access to the private and public sector. The network stretches across Salford, Trafford and the city of Manchester. For further information visit https://www.theloopmanchester.co.uk/
View source version on businesswire.com: https://www.businesswire.com/news/home/20201231005050/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom